Charles CattonMD, FRCPC
Professor

Contact Info

T. (416) 946-2121
F. (416) 946-4586

Location

Princess Margaret Cancer Centre
610 University Avenue
Toronto
ON, M5G 2M9

Clinical Interests

GU tumours, prostate cancer, Sarcoma, Development of high-precision radiation techniques for the treatment of GU and soft tissue malignancies

Accepting

Please contact Faculty Member for more information

Degree/Qualifications

MD, University of Ottawa
FRCPC, Radiation Oncology

Professional Memberships

Executive Member GU disease Oriented Group, NCIC-CTG

Appointments

Professor, Department of Radiation Oncology, University of Toronto
Radiation Oncologist, Department of Radiation Oncology, Princess Margaret Hospital/ University Health Network
GU site group leader, Princess Margaret Hospital/ University Health Network

Research/Teaching

Research Synopsis:

  • A Phase III trial of Hypofractionated vs conventional escalated dose radiotherapy for localized prostate cancer (P.I.) (Acronym PROFIT, sponsored by Ontario Clinical Oncology Group)
  • A Phase III trial of immediate vs early salvage post-operative radiotherapy for limited-stage prostate cancer, with long term, short term or no androgen ablation. (P.I.) (Acronym RADICALS, NCIC-CTG designation PR-13. Sponsors NCIC-CTG and MRC UK)

Publications and Awards

Recent Publications

Smitsmans MH, de Bois J, Sonke JJ, Catton CN, Jaffray DA, Lebesque JV, van Herk M. Residual seminal vesicle displacement in marker-based image-guided radiotherapy for prostate cancer and the impact on margin design.Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):590-6. Epub 2010 Oct 1.

Rosewall T, Catton C, Currie G, Bayley A, Chung P, Wheat J, Milosevic M. The relationship between external beam radiotherapy dose and chronic urinary dysfunction–a methodological critique Radiother Oncol. 2010 Oct; 97(1):40-7.

Baxi S, Catton C. Practice patterns for post-prostatectomy hormonal therapy amongst Canadian radiation oncologists. Can J Urol. 2010 Dec;17(6):5436-41.

Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Apr 6. [Epub ahead of print]

Dickie CI, Griffin AM, Parent AL, Chung PW, Catton CN, Svensson J, Ferguson PC, Wunder JS, Bell RS, Sharpe MB, O’Sullivan B. The Relationship Between Local Recurrence and Radiotherapy Treatment Volume for Soft Tissue Sarcomas Treated with External Beam Radiotherapy and Function Preservation Surgery. Int J Radiat Oncol Biol Phys. 2011 Jun 1. [Epub ahead of print] Collaborator

Middleton M, Frantzis J, Healy B, Jones M, Murry R, Kron T, Plank A, Catton C, Martin J.Successful Implementation of Image-Guided Radiation Therapy Quality Assurance in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study.Int J Radiat Oncol Biol Phys. 2010 Nov 11. [Epub ahead of print]

 

Back to Top